Related Experiment Video
Updated: Nov 11, 2025

Author Spotlight: Developing a Translational Model for Atrial Fibrillation Research Across Species
Published on: November 21, 2023
Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible
Stanley Nattel1,2,3,4, Philip T Sager5, Jörg Hüser6
1Department of Medicine, Montreal Heart Institute and Université de Montréal, Montreal, Canada.
Abstract:
Atrial fibrillation (AF) is the most common sustained clinical arrhythmia, with a lifetime incidence of up to 37%, and is a major contributor to population morbidity and mortality. Important components of AF management include control of cardiac rhythm, rate, and thromboembolic risk. In this narrative review article, we focus on rhythm-control therapy. The available therapies for cardiac rhythm control include antiarrhythmic drugs and catheter-based ablation procedures; both of these are presently neither optimally effective nor safe. In order to develop improved treatment options, it is necessary to use preclinical models, both to identify novel mechanism-based therapeutic targets and to test the effects of putative therapies before initiating clinical trials. Extensive research over the past 30 years has provided many insights into AF mechanisms that can be used to design new rhythm-maintenance approaches. However, it has proven very difficult to translate these mechanistic discoveries into clinically applicable safe and effective new therapies. The aim of this article is to explore the challenges that underlie this phenomenon. We begin by considering the basic problem of AF, including its clinical importance, the current therapeutic landscape, the drug development pipeline, and the notion of upstream therapy. We then discuss the currently available preclinical models of AF and their limitations, and move on to regulatory hurdles and considerations and then review industry concerns and strategies. Finally, we evaluate potential paths forward, attempting to derive insights from the developmental history of currently used approaches and suggesting possible paths for the future. While the introduction of successful conceptually innovative new treatments for AF control is proving extremely difficult, one significant breakthrough is likely to revolutionize both AF management and the therapeutic development landscape.
Related Concept Videos
Dysrhythmias VI: Management of Dysrhythmias
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Clinical Trials: Overview

